Scalper1 News
Medical giant Johnson & Johnson (JNJ) early Tuesday delivered strong quarterly results, led by its hepatitis C drug Olysio. But J&J stock slid nearly 1.5% in morning trading, as the company does not expect the growth rate to continue. J&J’s earnings, excluding one-time items, rose 12% over the year-earlier quarter to $1.66 a share, beating analysts’ consensus by 11 cents. Sales rose 9% to $19.5 billion, about $500 million above estimates. The Scalper1 News
Scalper1 News